ErbB2/Her2 anticorps (pTyr1112)

N° du produit ABIN1881304

Cet anticorps Lapin Polyclonal détecte spécifiquement ErbB2/Her2 dans WB et DB. Il présente une réactivité envers Humain et a été mentionné dans 5+ publications.

Aperçu rapide pour ErbB2/Her2 anticorps (pTyr1112) (ABIN1881304)

Antigène: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp ErbB2/Her2 est non-conjugé

Application: Western Blotting (WB), Dot Blot (DB)

Clone: RB40063

Détail du produit anti-ErbB2/Her2 anticorps

Épitope: pTyr1112

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogène: This ErbB2 Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y1112 of human ErbB2.

Isotype: Ig Fraction

Information d'application

Indications d'application: WB: 1:2000. DB: 1:500

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Date de péremption: 6 months

Références pour anticorps anti-ErbB2/Her2 (ABIN1881304)

Mándoky, Géczi, Bodrogi, Tóth, Csuka, Kásler, Bak: "Clinical relevance of HER-2/neu expression in germ-cell testicular tumors." dans: Anticancer research, Vol. 24, Issue 4, pp. 2219-24, (2004) (PubMed).

Contreras, Cobos, Lox: "Is the circulating urokinase plasminogen activator upregulated by the circulating p105 fraction of the HER-2/neu proto-oncogene in patients with cervical cancer?" dans: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, Vol. 10, Issue 3, pp. 271-6, (2004) (PubMed).

Stephens, Hunter, Bignell, Edkins, Davies, Teague, Stevens, OMeara, Smith, Parker, Barthorpe, Blow, Brackenbury, Butler, Clarke, Cole, Dicks, Dike, Drozd, Edwards, Forbes, Foster, Gray, Greenman et al.: "Lung cancer: intragenic ERBB2 kinase mutations in tumours. ..." dans: Nature, Vol. 431, Issue 7008, pp. 525-6, (2004) (PubMed).

Wang, Lien, Xia, Chen, Lo, Wang, Ali-Seyed, Lee, Bartholomeusz, Ou-Yang, Giri, Hung: "Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2." dans: Cancer cell, Vol. 6, Issue 3, pp. 251-61, (2004) (PubMed).

Menendez, Vellon, Mehmi, Oza, Ropero, Colomer, Lupu: "Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, Issue 29, pp. 10715-20, (2004) (PubMed).

Détails sur ErbB2/Her2

Antigène: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Autre désignation: ERBB2

Sujet: ErbB2 is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors.

Poids moléculaire: 137910

NCBI Accession: NP_001005862, NP_004439

UniProt: P04626

Pathways: Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Skeletal Muscle Fiber Development